Oslo, 18 February 2025
Reference is made to the stock exchange announcement by Oncoinvent ASA
("Oncoinvent" or the "Company") on 6 February 2025 regarding the final result of
the subsequent offering in the Company, where a total of 5,500,000 new shares
were subscribed and allocated at a subscription price of NOK 2 per share.
The share capital increase pertaining to the subsequent offering has today been
registered with the Norwegian Register of Business Enterprises (Nw.
Foretaksregisteret). The Company's registered share capital is NOK 9,774,334.30
divided into 97,743,343 shares, each with a nominal value of NOK 0.10.
The new shares will be issued in the Norwegian Central Securities Depository
(ES-OSL) on the same ISIN as the other shares in the Company (ISIN NO
0010779341) and are expected to be delivered to the respective subscribers'
ES-OSL accounts on or about 18 February 2025.
This information is subject to the disclosure requirements pursuant to section
5-12 of the Norwegian Securities Trading Act.
About Oncoinvent
Oncoinvent ASA is a clinical stage, radiopharmaceutical company developing
innovative treatments for solid cancers. The technology platform is focused on
the use of alpha-emitting radionuclides to deliver powerful radiation directly
to cancer cells. The Company's lead product candidate, Radspherin®, is being
advanced through clinical development by a team with experience from all stages
of radiopharmaceutical development. Internal manufacturing and supply chain
capabilities have been established, which now have the capacity to supply
Radspherin® for multi-center phase 2 clinical studies.
For further information, please contact:
Øystein Soug, Chief Executive Officer
Email: soug@oncoinvent.com
Tore Kvam, Chief Financial Officer
Email: kvam@oncoinvent.com